Study Links GLP-1 Weight-Loss Medications to Nail and Hair Issues
Recent research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 in Vienna has revealed concerning side effects associated with GLP-1 medications, commonly used for obesity and diabetes management. The study found that individuals taking these medications reported nail detachment and hair loss at significantly higher rates than those who do not use GLP-1s.
The investigation involved two studies that evaluated 575 GLP-1 users and a control group of 1,329 individuals with similar health profiles who did not take the drugs. Participants were recruited from various countries, including France, the United States, Brazil, and Mexico. In the primary study focusing on nail health, 39% of GLP-1 users reported experiencing nail detachment, compared to just 9% of non-users. Additionally, 46% of those using GLP-1 medications reported nail discoloration, while only 17% of the control group experienced similar issues. Overall, 66% of GLP-1 users reported at least one nail disorder, compared to 53% among non-users.
Importantly, the researchers noted that weight loss alone could not account for the increased incidence of these nail issues. Even among participants who lost weight, those taking GLP-1 medications were still more likely to experience nail detachment and discoloration. After adjusting for existing dermatological conditions and nutritional deficiencies, the differences remained significant, with nail detachment and discoloration occurring two to three times more frequently among GLP-1 users.
Dr. Charles Taïeb, a clinical dermatologist involved in the study, emphasized that while the findings show a clear association between GLP-1 therapy and nail changes, it is crucial to understand that not all effects observed during treatment are necessarily caused by the medication itself.
In a related study assessing hair and scalp conditions, 50% of GLP-1 users reported unusual hair loss, compared to 34% of the control group. After starting treatment, 26% of GLP-1 users noted hair loss or thinning, while 42% experienced a reduction in hair volume. Scalp inflammation, including symptoms such as redness and itching, was reported more frequently among GLP-1 users, suggesting a possible inflammatory component rather than just the classic shedding often associated with rapid weight loss.
Dr. Bruno Halioua, another study author, indicated that the inflammatory symptoms observed may not be commonly recognized by clinicians, highlighting the importance of further research. He advised patients experiencing these symptoms to consult their healthcare providers rather than discontinuing their medication, as the changes are typically not severe enough to warrant stopping treatment.
The studies relied on patient-reported data and were conducted at a single point in time, meaning the findings indicate associations rather than causation. The research team plans to conduct further studies to explore the timing and potential causes of these changes, as well as whether they resolve over time.
These findings raise important considerations for individuals using GLP-1 medications, particularly regarding the management of side effects and the need for ongoing monitoring of dermatological health during treatment.




